Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech reported standalone revenue of Rs 1,055.07 crore for FY26, down from Rs 1,200.09 crore in FY25, representing approximately 12% revenue decline. Profit after tax fell to Rs 263.27 crore from Rs 372.96 crore in the prior year, a decline of about 29%. The company declared a dividend of Rs 7.55 per equity share. Auditors BSR & Co. LLP issued an unmodified (clean) opinion on both standalone and consolidated results. An exceptional charge of Rs 327.54 lakh was recorded due to the new labour codes. The company appointed Mrs. Ekta Gupta as Additional Independent Director and new internal and cost auditors for FY27.
The significant decline in both revenue and profit is a concern for shareholders. However, the clean audit opinion and dividend declaration provide some stability. The stock may face pressure due to the earnings contraction.